medline.ch Onkologie Respirationstrakt

	Multicentre randomised phase II study of the perioperative administration of flurbiprofen axetil in patients with non-small cell lung cancer: study protocol of the FLAX Study. BMJ Open Sakamaki K, Watanabe K, Woo T, Masuda M. PMID: 33257489 [PubMed - in process]
	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. Arch Med Res Baburaj G, Thomas L, Rao M. PMID: 33257051 [PubMed - as supplied by publisher]
	The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer. Technol Cancer Res Treat Tian WJ, Liu SS, Li BR. PMID: 33256552 [PubMed - in process]
	In Silico and In Vitro Analysis of lncRNA XIST Reveals a Panel of Possible Lung Cancer Regulators and a Five-Gene Diagnostic Signature. Cancers (Basel) Katopodis P, Dong Q, Halai H, Fratila CI, Polychronis A, Anikin V, Sisu C, Karteris E. PMID: 33255394 [PubMed]
	Management guidelines for stage III non-small cell lung cancer. Crit Rev Oncol Hematol Jazieh AR, Zeitouni M, Alghamdi M, Alrujaib M, Lotfi S, Abu Daff S, Alomair A, Alshehri S, Alhusaini H, Allehebi A, Ansari J, Alnassar M, Jafar H, Alfarsi A, Abdelhafeez N, Alkattan K. PMID: 33254035 [PubMed - as supplied by publisher]
	miRNAs in lung cancer. A systematic review identifies predictive and prognostic miRNA candidates for precision medicine in lung cancer. Transl Res Zhong S, Golpon H, Zardo P, Borlak J. PMID: 33253979 [PubMed - as supplied by publisher]
	Qualitative emphysema and risk of COPD hospitalization in a multicenter CT lung cancer screening cohort study. Respir Med Gazourian L, Thedinger WB, Regis SM, Pagura EJ, Price LL, Gawlik M, Stefanescu CF, Lamb C, Rieger-Christ KM, Singh H, Casasola M, Walker AR, Rupal A, Patel AS, Come CE, Sanayei AM, Long WP, Rizzo GS, McKee AB, Washko GR, San Jose Estepar R, Wald C, McKee BJ, Thomson CC, Liesching TN. PMID: 33253972 [PubMed - as supplied by publisher]
	Anlotinib for refractory advanced non-small-cell lung cancer: A systematic review and meta-analysis. PLoS One Yu G, Shen Y, Xu X, Zhong F. PMID: 33253313 [PubMed - in process]
	The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers. Mol Oncol Kalinke L, Thakrar R, Janes SM. PMID: 33252175 [PubMed - as supplied by publisher]
	Serum miR-185 Is a Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer. Technol Cancer Res Treat Liu J, Han Y, Liu X, Wei S. PMID: 33251978 [PubMed - in process]
	Preclinical Metrics Correlate With Drug Activity in Phase II Trials of Targeted Therapies for Non-Small Cell Lung Cancer. Front Oncol Rybinski B, Hosgood HD, Wiener SL, Weiser DA. PMID: 33251146 [PubMed]
	Survival Nomogram for Stage IB Non-Small-Cell Lung Cancer Patients, Based on the SEER Database and an External Validation Cohort. Ann Surg Oncol Zuo Z, Zhang G, Song P, Yang J, Li S, Zhong Z, Tan Q, Wang L, Xue Q, Gao S, Sun N, He J. PMID: 33249521 [PubMed - as supplied by publisher]
	Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. Lung Cancer Wu YL, Shi Y, Tan DSW, Xiaoqing L, Cheng Y, Zhou J, An TT, Lu Y, Zhu B, Bai C, Passos VQ, Lau YY, Xun L, Zhang L. PMID: 33249379 [PubMed - as supplied by publisher]
	The prognostic value of the tumor-stroma ratio in squamous cell lung cancer, a cohort study. Cancer Treat Res Commun Smit MA, Philipsen MW, Postmus PE, Putter H, Tollenaar RA, Cohen D, Mesker WE. PMID: 33249210 [PubMed - as supplied by publisher]
	Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. J Thorac Oncol Nishio M, Yoshida T, Kumagai T, Hida T, Toyozawa R, Shimokawaji T, Goto K, Nakagawa K, Ohe Y, Seto T, Kudou K, Asato T, Zhang P, Yamamoto N. PMID: 33248320 [PubMed - as supplied by publisher]
	Immunosuppressive role of Benzo[a]pyrene in induction of lung cancer in mice. Chem Biol Interact Salem ML, El-Ashmawy NE, Abd El-Fattah EE, Khedr EG. PMID: 33245929 [PubMed - as supplied by publisher]
	Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study. Front Oncol Zhao S, Zhang Z, Fang W, Zhang Y, Zhang Z, Hong S, Ma Y, Zhou T, Yang Y, Huang Y, Zhao H, Zhang L. PMID: 33244458 [PubMed]
	Early diagnosis of lung cancer in people most at risk. Br J Gen Pract Sullivan FM, van Beusekom M. PMID: 33243902 [PubMed - in process]
	Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China. BMJ Open Liu Q, Luo X, Peng L, Yi L, Wan X, Zeng X, Tan C. PMID: 33243806 [PubMed - in process]
	Nurse-led, screening-triggered, early specialised palliative care intervention programme for patients with advanced lung cancer: study protocol for a multicentre randomised controlled trial. BMJ Open Fujisawa D, Umemura S, Okizaki A, Satomi E, Yamaguchi T, Miyaji T, Mashiko T, Kobayashi N, Kinoshita H, Mori M, Morita T, Uchitomi Y, Goto K, Ohe Y, Matsumoto Y. PMID: 33243791 [PubMed - in process]

Artikel 1 - 20 / 111426

Seite 1 von 5572

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung